Summary of 2024 updates
Updated December 2024
- Clarification that quantitative ultrasound, IBEX bone health, and Radiofrequency Echographic Multi Spectrometry are not recommended for the diagnosis of osteoporosis
- Advice added on use of FRAX in non-white ethnic groups and those who have migrated to the UK
- FRAX adjustment added for patients with Parkinson’s disease
- Additional clinical risk factors for increased fracture risk have been added: lower limb amputation and adult learning disabilities: e.g., Down’s Syndrome
- Advice added on use of FRAX in non-white ethnic groups and those who have migrated to the UK
- The definition of very high fracture risk has been clarified
- The intervention threshold has been defined and the associated graphs updated
- Vaping with e-cigarettes has been added as a possible risk factor for fragility fracture
- HRT is now recommended as a first line treatment option in younger postmenopausal women (age ≤ 60 years) with high fracture risk and low baseline risk for adverse malignant and thromboembolic events
- Recommendations pertaining to the use of abaloparatide have been added
- Considerations when choosing which anabolic agent to use have been outlined
- Additional training resources have been added
- Membership of NOGG has been updated
- These have been updated in line with the above revisions
- This has been updated in line with the above revisions